Overview

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

 
  • Current Quote
  • Stock Chart
NASDAQ:CTIC
$1.910.00 (0.00%)
Day High:$1.93
Day Low:$1.84
Volume:0
09/19/184:00 p.m. ET
Delayed at least 15 minutes.

Julia Balanova
Ph + 646 378 2936
jbalanova@soleburytrout.com


 

Recent News

MORE
DateTitle 
Aug 02, 2018CTI BioPharma Reports Second Quarter 2018 Financial Results
-Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time- SEATTLE, Aug. 2, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the second quarter and six months ended June 30, 2018. In July 2018, CTI BioPharma announced the continuation without modification of the PAC203 Phase 2 study following a planned interim review by an Independent Data Monitoring Committee. The Company also announced a pacritinib program update following a ... 
Printer Friendly Version
Jul 26, 2018CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018
SEATTLE, July 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2018 financial results on Thursday, August 2, 2018, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows: Thur... 
Printer Friendly Version
Jul 18, 2018CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA
- Regulatory path to include Phase 3 trial expected to begin in 2019 - - Company to request additional meeting with FDA following second interim review of PAC203 - SEATTLE, July 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it recently conducted a Type B meeting with the U.S. Food and Drug Administration (FDA) for its lead product candidate pacritinib. The purpose of the meeting was to discuss the regulatory pathway for pacritinib. Based on FDA feedback,... 
Printer Friendly Version

Events

MORE
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.